美国液体栓塞剂市场规模、份额和趋势分析报告：按产品、应用、最终用途和细分市场预测，2025 年至 2033 年

美国液态栓塞剂市场摘要

美国液体栓塞剂市场规模预计在 2024 年达到 6,697 万美元，预计到 2033 年将达到 1.4685 亿美元，2025 年至 2033 年的复合年增长率为 9.26%。推动这一增长的因素包括技术进步、血管疾病患病率的上升、对微创手术的偏好日益增长、栓塞剂材料的进步以及应用领域的不断扩大。

神经血管疾病和周边血管疾病（例如动脉瘤、动静脉畸形 (AVM) 和富血管肿瘤）的发生率日益上升，推动了对有效栓塞解决方案的需求，并刺激了市场扩张。这些疾病通常需要微创手术来阻断异常血管、防止破裂或减少肿瘤的血液供应。液体栓塞剂尤其适合这些治疗，因为它们能够精准靶向复杂的血管结构，有效消除血管，同时最大限度地减少附带损害。

随着对这些疾病的认识不断提高和诊断技术的进步，越来越多的患者被早期诊断并需要栓塞治疗。此外，氰基丙烯酸正丁酯 (n-BCA) 和乙烯 - 乙烯醇共聚物 (EVOH) 等栓塞材料的进步提高了这些手术的安全性和有效性，使其成为对临床医生更具吸引力的选择。血管内手术的日益普及进一步推动了液体栓塞剂的使用。因此，神经血管和周边血管病例的激增、技术进步以及临床接受度的提高正在推动市场扩张。例如，美敦力公司于 2025 年 7 月宣布招募週边 Onyx 液体栓塞 (PELE) 临床试验的第一位患者。该试验旨在评估 Onyx 液体栓塞系统 (LES) 对週边血管动脉出血进行栓塞的安全性和有效性。

液体栓塞剂广泛用于治疗各种疾病，包括动静脉畸形 (AVM)、富血管肿瘤、週边出血和其他血管异常。中风、癌症和创伤的发生率上升，推动了美国对有效栓塞疗法的需求不断增长。例如，根据巴罗神经学研究所的数据，约有 30 万美国人患有脑部或脊髓动静脉畸形（神经动静脉畸形），但只有约 12% 的患者会出现症状。

在美国营运美国FDA核准产品的主要企业包括Medtronic、Serenobus（强生）、波士顿科学公司、Terumo Corporation、Sirtex（黑天鹅血管）等。此外，氰基丙烯酸酯、非黏附性材料和乙烯 - 乙烯醇共聚物等先进栓塞材料的采用提高了治疗效果和安全性，刺激了市场扩张。

门诊手术的趋势也促进了市场的成长，门诊手术中心越来越多地采用栓塞治疗，因为它具有成本效益和患者便利性。根据 2022 年 4 月发表在《介入性神经放射学》上的一篇研究论文，美国医院正在利用液体栓塞系统 (LES)，例如氰基丙烯酸正丁酯 (n-BCA) 和乙烯 - 乙烯醇共聚物 (EVOH)，对脑动静脉畸形 (bAVM) 进行栓塞，以促进术前重组。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国液态栓塞剂市场变数、趋势与范围

• 市场体系展望
  • 补贴市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
  • 市场机会分析
  • 市场问题分析
• 美国液态栓塞剂市场分析工具
  • 产业分析-波特五力分析
  • PESTEL分析

第四章美国液体栓塞剂市场：按产品分類的估计和趋势分析

• 细分仪表板
• 美国液态栓塞剂市场产品波动分析
• 2021-2033 年美国液态栓塞剂市场规模及产品趋势分析
• 乙烯 - 乙烯醇共聚物（EVOH）
• 氰基丙烯酸酯
  • N-BCA
  • N-HCA
• 其他的

第五章美国液体栓塞剂市场：应用预测与趋势分析

• 细分仪表板
• 美国液态栓塞剂市场应用波动分析
• 美国液态栓塞剂市场规模及应用趋势分析（2021-2033）
• 动静脉畸形（AVM）
• 富血管肿瘤
• 週边血管出血
• 其他的

第六章：美国液体栓塞剂市场：按最终用途的估计和趋势分析

• 细分仪表板
• 美国液态栓塞剂市场最终用途波动分析
• 美国液态栓塞剂市场规模及趋势分析（依最终用途），2021-2033 年
• 医院
• 专科诊所
• 门诊手术中心
• 其他的

第七章 竞争态势

• 市场参与企业分类
• 主要企业简介
  • Medtronic
  • Terumo
  • Boston Scientific Corporation
  • Johnson &Johnson
  • Sirtex（BlackSwan Vascular, Inc.）
  • Others
• 2024年公司市场占有率分析
• 其他主要市场公司名单

U.S. Liquid Embolic Agent Market Summary

The U.S. liquid embolic agent market size was estimated at USD 66.97 million in 2024 and is projected to reach USD 146.85 million by 2033, growing at a CAGR of 9.26% from 2025 to 2033. This growth is driven by technological advancements, increasing prevalence of vascular disorders, rising preference for minimally invasive procedures, advancements in embolic agent materials, and expanding application areas.

The increasing incidence of neurovascular and peripheral vascular conditions such as aneurysms, arteriovenous malformations (AVMs), and hypervascular tumors has increased demand for effective embolization solutions, fueling market expansion. These conditions often require minimally invasive procedures to block abnormal blood vessels, prevent rupture, or reduce tumor blood supply. Liquid embolic agents are particularly well-suited for these treatments because they precisely target complex vascular structures, providing effective devascularization with minimal collateral damage.

As awareness of these conditions increases and diagnostic techniques improve, more patients are diagnosed early and require embolization therapy. In addition, advancements in embolic materials, such as n-butyl cyanoacrylate (n-BCA) and ethylene vinyl alcohol copolymer (EVOH), have enhanced the safety and efficacy of these procedures, making them more attractive options for clinicians. The expanding adoption of endovascular techniques further boosts the utilization of liquid embolic agents. Consequently, this surge in neurovascular and peripheral vascular condition cases, technological progress, and growing clinical acceptance fuel market expansion. For instance, in July 2025, Medtronic announced the enrollment of the first patient in the Peripheral Onyx Liquid Embolic (PELE) clinical trial. This study aims to assess the safety and efficacy of the Onyx Liquid Embolic System (LES) for the embolization of arterial hemorrhages in the peripheral vasculature.

Liquid embolic agents are widely used in the treatment of various conditions such as arteriovenous malformations (AVMs), hypervascular tumors, peripheral hemorrhages, and other vascular anomalies. The growing incidence of stroke, cancer, and traumatic injuries has increased demand for effective embolization therapies in the country. For instance, according to Barrow Neurological Institute, approximately 300,000 Americans are affected by AVMs of the brain and spinal cord (neurological AVMs), but only around 12 percent of those affected experience symptoms.

Some of the key players operating in the U.S. and having U.S. FDA-approved products include Medtronic, CERENOVUS (Johnson & Johnson), Boston Scientific Corporation, Terumo, and Sirtex (BlackSwan Vascular, Inc.). Furthermore, the adoption of advanced embolic materials, including cyanoacrylate-based, non-adhesive, and ethylene vinyl alcohol copolymer agents, has improved procedural outcomes and safety profiles, fueling market expansion.

The trend toward outpatient procedures is also contributing to market growth, with ambulatory surgical centers increasingly adopting embolization techniques due to their cost-effectiveness and patient convenience. According to a research article published in the Interventional Neuroradiology journal in April 2022, liquid embolic systems (LESs) such as n-butyl cyanoacrylate (n-BCA) and ethylene vinyl alcohol copolymer (EVOH) are utilized for the embolization of brain arteriovenous malformations (bAVMs) to facilitate presurgical devascularization in U.S. hospitals.

U.S. Liquid Embolic Agent Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. liquid embolic agent market report based on product, application, and end use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Ethylene Vinyl Alcohol Copolymer (EVOH)
• Cyanoacrylates
  • N-BCA
  • N-HCA
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Arteriovenous Malformations (AVM)
• Hypervascular Tumors
• Peripheral Vasculature Hemorrhage
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Ambulatory Surgery Centers
• Other End Use

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
  • 1.5.5. Information Analysis
  • 1.5.6. Data Analysis Models
• 1.6. Market Formulation & Data Visualization
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List of Secondary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Liquid Embolic Agent Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing incidence of conditions such as arteriovenous malformations (AVMs), aneurysms, and hemorrhages necessitates embolization procedures
    • 3.2.1.2. Advancements in embolization technologies
    • 3.2.1.3. Increasing adoption in oncology treatments
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of materials and procedures
    • 3.2.2.2. Strict regulatory approvals and compliance
  • 3.2.3. Market Opportunities Analysis
    • 3.2.3.1. Emerging applications
  • 3.2.4. Market Challenges Analysis
• 3.3. U.S. Liquid Embolic Agent Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. U.S. Liquid Embolic Agent Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Liquid Embolic Agent Market Product Movement Analysis
• 4.3. U.S. Liquid Embolic Agent Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Ethylene Vinyl Alcohol Copolymer (EVOH)
  • 4.4.1. Ethylene Vinyl Alcohol Copolymer (EVOH) U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Cyanoacrylates
  • 4.5.1. Cyanoacrylates U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. N-BCA
    • 4.5.2.1. N-BCA U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. N-HCA
    • 4.5.3.1. N-HCA U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Others U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Liquid Embolic Agent Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Liquid Embolic Agent Market Application Movement Analysis
• 5.3. U.S. Liquid Embolic Agent Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Arteriovenous Malformations (AVM)
  • 5.4.1. Arteriovenous Malformations (AVM) U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Hypervascular Tumors
  • 5.5.1. Hypervascular Tumors U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Peripheral Vasculature Hemorrhage
  • 5.6.1. Peripheral Vasculature Hemorrhage U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Liquid Embolic Agent Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Liquid Embolic Agent Market End Use Movement Analysis
• 6.3. U.S. Liquid Embolic Agent Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Specialty Clinics
  • 6.5.1. Specialty Clinics U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Ambulatory Surgery Centers
  • 6.6.1. Ambulatory Surgery Centers U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Other End Use
  • 6.7.1. Other End Use U.S. Liquid Embolic Agent Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Key Company Profiles
  • 7.2.1. Medtronic
    • 7.2.1.1. Company Overview
    • 7.2.1.2. Financial Performance
    • 7.2.1.3. Product Benchmarking
    • 7.2.1.4. Strategic Initiatives
  • 7.2.2. Terumo
    • 7.2.2.1. Company Overview
    • 7.2.2.2. Financial Performance
    • 7.2.2.3. Product Benchmarking
    • 7.2.2.4. Strategic Initiatives
  • 7.2.3. Boston Scientific Corporation
    • 7.2.3.1. Company Overview
    • 7.2.3.2. Financial Performance
    • 7.2.3.3. Product Benchmarking
    • 7.2.3.4. Strategic Initiatives
  • 7.2.4. Johnson & Johnson
    • 7.2.4.1. Company Overview
    • 7.2.4.2. Financial Performance
    • 7.2.4.3. Product Benchmarking
    • 7.2.4.4. Strategic Initiatives
  • 7.2.5. Sirtex (BlackSwan Vascular, Inc.)
    • 7.2.5.1. Company Overview
    • 7.2.5.2. Financial Performance
    • 7.2.5.3. Product Benchmarking
    • 7.2.5.4. Strategic Initiatives
  • 7.2.6. Others
    • 7.2.6.1. Company Overview
    • 7.2.6.2. Financial Performance
    • 7.2.6.3. Product Benchmarking
    • 7.2.6.4. Strategic Initiatives
• 7.3. Company Market Share Analysis, 2024
• 7.4. List of Other Key Market Players

List of Tables

• Table 1. List of Secondary Sources
• Table 2. List of Abbreviations
• Table 3. U.S. Liquid Embolic Agent Market, by Product, 2021 - 2033 (USD Million)
• Table 4. U.S. Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 5. U.S. Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 6. Participant's Overview
• Table 7. Financial Performance
• Table 8. Product Benchmarking
• Table 9. Strategic Initiatives

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 U.S. Liquid Embolic Agent Market, Market Segmentation
• Fig. 7 Market Driver Analysis (Current & Future Impact)
• Fig. 8 Market Restraint Analysis (Current & Future Impact)
• Fig. 9 Market Opportunity Analysis (Current & Future Impact)
• Fig. 10 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 11 Porter's Five Forces Analysis
• Fig. 12 Regional Marketplace: Key Takeaways
• Fig. 13 U.S. Liquid Embolic Agent Market, for Product, 2021 - 2033 (USD Million)
• Fig. 14 U.S. Liquid Embolic Agent Market, for Ethylene Vinyl Alcohol Copolymer (EVOH), 2021 - 2033 (USD Million)
• Fig. 15 U.S. Liquid Embolic Agent Market, for Cyanoacrylates, 2021 - 2033 (USD Million)
• Fig. 16 U.S. Liquid Embolic Agent Market, for N-BCA, 2021 - 2033 (USD Million)
• Fig. 17 U.S. Liquid Embolic Agent Market, for N-HCA, 2021 - 2033 (USD Million)
• Fig. 18 U.S. Liquid Embolic Agent Market, for Others, 2021 - 2033 (USD Million)
• Fig. 19 U.S. Liquid Embolic Agent Market, for Arteriovenous Malformations (AVM), 2021 - 2033 (USD Million)
• Fig. 20 U.S. Liquid Embolic Agent Market, for Hypervascular Tumors, 2021 - 2033 (USD Million)
• Fig. 21 U.S. Liquid Embolic Agent Market, for Peripheral Vasculature Hemorrhage, 2021 - 2033 (USD Million)
• Fig. 22 U.S. Liquid Embolic Agent Market, for Others, 2021 - 2033 (USD Million)
• Fig. 23 U.S. Liquid Embolic Agent Market, for End Use, 2021 - 2033 (USD Million)
• Fig. 24 U.S. Liquid Embolic Agent Market, for Hospitals, 2021 - 2033 (USD Million)
• Fig. 25 U.S. Liquid Embolic Agent Market, for Specialty Clinics, 2021 - 2033 (USD Million)
• Fig. 26 U.S. Liquid Embolic Agent Market, for Ambulatory Surgery Centers, 2021 - 2033 (USD Million)
• Fig. 27 U.S. Liquid Embolic Agent Market, for Other End Use, 2021 - 2033 (USD Million)